We found that women ages 45 to 64 were the largest patient group to have received prescriptions and that nurse practitioners had written more prescriptions than any other prescribing provider speciality to this group
Tirzepatide is a dual agonist, targeting the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, while retatrutide is a triple agonist, targeting GIP, GLP-1, and GCG simultaneously
In studies with rodents, Wegovy and medicines that work like Wegovy caused thyroid tumors, including thyroid cancer
GLP-1 receptor agonists like liraglutide and semaglutide are popular weight loss tools for people with diabetes, obesity or excess body weight
Dont use either medication if you have a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2
Whilst highly effective, these medications can cause gastrointestinal side effects including nausea, vomiting, and diarrhoea, potentially leading to fluid and electrolyte losses